Dear valued MATRx customer,
The MATRx in-lab was cleared by the Food and Drug Administration (FDA) in March, 2012 and was released in the US in the fall of the same year. A lot has happened since the fall of 2012: i) in-lab PSG studies are increasingly being replaced by home sleep testing; and, ii) reimbursement rates and availability of medical insurance for in-lab PSG is becoming more limited. In-lab titration studies for the MATRx continue in the US, however, are no longer at a level which support a commercial effort and for this reason, effective immediately, we have made the tough decision to issue an End of Life Notice for the MATRx titration system. Fortunately, we have a replacement product, the MATRx plus.
We understand that this notice may be unwelcome news, to help with the transition for our many loyal customers, titration trays and spare parts will continue to be available for purchase until April 2020. We will continue to provide technical support and training until December 31st, 2020. We will honor all of our warranty obligations. Should you have any questions on the End of Life Notice, please contact us.
While the MATRx in-lab product has only been a limited commercial success, it has been a significant strategic success. Health professionals using the MATRx in-lab, have taught us all the importance of pre-testing an OSA patient for oral appliance treatment. Sleep Physicians now confidently prescribe oral appliances after completing a MATRx test. Further, by providing a dentist with the knowledge that a patient will respond favourably to treatment and by offering a therapeutic protrusive position, time-to-treatment is significantly reduced, and treatment effectiveness is significantly increased.
In August, 2018 the FDA approved the MATRx plus for use in the US. The MATRx plus is a tablet-based and cloud-connected Class II medical device designed for home use. The MATRx plus automatically titrates the patient (in the comfort of their home) delivering the same valuable information as the MATRx (patient response to treatment and therapeutic position). The first MATRx plus devices rolled off our production line in October and are already installed in over 220 sites, we are targeting over 800 installations by the end of 2019. The MATRx plus, standing on the shoulders of the MATRx, is already a commercial success and builds on the knowledge and understanding of the over 200 sleep labs and clinics which currently offer MATRx in-lab testing. Our hope is to migrate these sites over to the MATRx plus over the next 12 months and we are offering special incentives to assist our customers in the transition – please contact us for details or click the button below.
In addition, the MATRx plus can be configured as a level III PSG (HST) for those customers looking to do both diagnostics and theragnostics. The tablet-based design makes it easy for a patient to set themselves up for testing (on screen videos walk the patient through the process) and cloud-connectivity provides better customer support (we can dial into the device) and the ability to score tests remotely. Incomplete, failed or inconclusive tests can be reset remotely saving patients the time and effort of going back and forth from the sleep lab, hospital or dentist’s office. We continue to invest in research and development to enhance our offerings to the market.
Thank you for supporting our Company and products for all of these years and we look forward to servicing your needs well into the future.
If you have any questions or would like information on the MATRx plus – please contact us at email@example.com or call us at 1 (877) 341-8814.
Founder and CEO